Pfizer (PFE) and Valena Begin Phase 2 Study for Lyme Disease Vaccine Candidate

Go back to Pfizer (PFE) and Valena Begin Phase 2 Study for Lyme Disease Vaccine Candidate

Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate

March 8, 2021 1:00 AM EST

The Phase 2 study will include both adult and pediatric subjects with an aim to support acceleration of the vaccine candidates pediatric program  VLA15 will be  tested at two different schedules (Month 0-2-6 or Month 0-6) receiving the selected dose of 180µg VLA15 is the only Lyme disease vaccine candidate in active clinical development

Saint-Herblain (France) and New York, NY, March 8, 2021... More